It's the end of 2012, and that means it's time to take a look back at the year in retrospect. We'll be reading through the naughty and nice list (we've already checked it twice), counting down the 25 best-performing stocks and the 25 worst-performing stocks in the health care sector this year.
In this segment, Motley Fool health care analysts Brenton Flynn and Max Macaluso take a look at No. 24 on the naughty list: Halozyme Therapeutics (NASDAQ:HALO) and why this company deserves coal in its stocking.
Brenton Flynn, Max Macaluso, and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.